|1.||Hanrieder, Jörg: 2 articles (01/2012 - 01/2011)|
|2.||Andersson, Malin: 2 articles (01/2012 - 01/2011)|
|3.||Ljungdahl, Anna: 2 articles (01/2012 - 01/2011)|
|4.||Mellstrom, Britt: 1 article (01/2015)|
|5.||Moratalla, Rosario: 1 article (01/2015)|
|6.||Vallejo, Mario: 1 article (01/2015)|
|7.||Naranjo, Jose R: 1 article (01/2015)|
|8.||Ruiz-DeDiego, Irene: 1 article (01/2015)|
|9.||Bergquist, Jonas: 1 article (01/2011)|
|10.||Fälth, Maria: 1 article (01/2011)|
01/01/2011 - "Nigral levels of dynorphin B and alpha-neoendorphin strongly correlated with the severity of dyskinesia. "
01/15/2015 - "The protein DREAM decreases development of L-DOPA-induced dyskinesia in mice and reduces L-DOPA-induced expression of FosB, phosphoacetylated histone H3, and dynorphin-B in the striatum. "
01/01/2012 - "In the examples presented here, the peak intensities of dynorphin B, alpha-neoendorphin and substance P were found to be significantly increased in the dorsolateral, but not the dorsomedial, striatum of animals with severe dyskinesia involving facial, trunk and orolingual muscles (Fig. "
01/15/2015 - "Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well as FosB and dynorphin-B expression mediated by dopamine D1 receptor stimulation in the development of 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesia. "
01/01/2011 - "The nigral dynorphins associated with L-DOPA-induced dyskinesia were not those with high affinity to kappa opioid receptors, but consisted of shorter peptides, mainly dynorphin B and alpha-neoendorphin that are known to bind and activate mu and delta opioid receptors. "
01/01/1999 - "This study used correlated quantitative light and electron microscopic immunohistochemistry to examine dynorphin B-like immunoreactivity (dyn B-LI) in the rat hippocampal mossy fiber pathway before and after seizures. "
01/01/1999 - "Morphometry of a peptidergic transmitter system: dynorphin B-like immunoreactivity in the rat hippocampal mossy fiber pathway before and after seizures."
|3.||Alzheimer Disease (Alzheimer's Disease)
02/09/1995 - "Competition studies with dynorphin B and alpha-neoendorphin gave flat inhibition curves with Hill coefficients of 0.31 +/- 0.04 and 0.49 +/- 0.09 in the control brains and 0.38 +/- 0.05 and 0.48 +/- 0.08 in the Alzheimer's disease brains, respectively. "
02/09/1995 - "The pI50 values for dynorphin B and alpha-neoendorphin were 8.73 +/- 0.17 and 8.48 +/- 0.09, respectively, in the control brains and 9.30 +/- 0.22 and 8.70 +/- 0.15 in the Alzheimer's disease brains. "
|4.||Hypertension (High Blood Pressure)
09/12/1994 - "These results suggest (i) that dentate granule cells represent a discrete neural site that may exert a tonic inhibitory influence on blood pressure, (ii) that dentate granule cells are not required for the full expression of hypertension in the SHR, and (iii) that chronic high levels of corticosterone can reduce dynorphin B levels in the dentate granule cells of normotensive rats."
11/01/1994 - "We assessed plasma beta-endorphin, met-enkephalin, dynorphin B, ANF and noradrenaline levels, blood pressure and heart rate values in eight normotensive offspring and in 10 young normotensive subjects with no family history of hypertension (controls) at rest and during two exercise tests: the first test performed with the infusion of placebo (1.5 ml/min saline) and the second test with the infusion of an opioid antagonist (9.5 micrograms/kg per min naloxone hydrochloride). "
|5.||Ganglion Cysts (Ganglion)
|2.||Levodopa (L Dopa)
|3.||Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
|4.||Dopamine D1 Receptors (Dopamine D1 Receptor)
|5.||Adenosine Monophosphate (AMP)
|10.||beta-Endorphin (Endorphin, beta)